Company Overview and News

313
Avenir Global Fund Q1 '18 Commentary: Long Synchrony

2018-05-01 seekingalpha
The Avenir Global Fund - Class I units (the "Class I Fund") declined 1.3%, net of fees, during the March 2018 quarter. The retail class of the Avenir Global Fund ("Avenir Global Fund") also declined 1.3%, net of fees, for the quarter and has increased 11.4%, net of fees, since inception on 25 August 2017. The MSCI ACWI index (in AUD) returned 1.0% for the March 2018 quarter while the S&P 500 returned negative 0.
LOW TGLS BXG CRMLY PYPL WMT AMZN HCA GM GE GEC C BBX SYF 0100 NXST DTG BABA GNE CRMLF DRTGF ADS

481
Mittleman Investment Management 1Q18 Commentary

2018-04-13 seekingalpha
Mittleman Investment Management, LLC's composite declined 11.3% net of fees in the first quarter of 2018, versus declines of 0.8% in the S&P 500 Total Return Index and 0.1% in the Russell 2000 Total Return Index. Longer-term results for our composite through 3/31/18 are presented below:
PM DB SGMS IGT RAD CRMLY VLRSY GAPFF AC BAC AMZN IRLTY CSCO PAA CCO IQV RGC MO AMC VRL VLRDF 0100 CKEC BRK.A BABA ACDVF PRAH VLRDY CRMLF ADS

0
Clear Media Ltd. ADR 2017 Q4 - Results - Earnings Call Slides

2018-04-09 seekingalpha
The following slide deck was published by Clear Media Ltd. ADR in conjunction with their 2017 Q4 earnings call.
CRMLY CRMLF 0100

16
Clear Channel Outdoors: iHeartMedia Bankruptcy Implications

2018-03-21 seekingalpha
iHeartMedia has used Clear Channel Outdoors, which it controls, as its own personal piggybank for years.
LSXMB BATRK FWONB LSXMA CRMLY BATRR 0100 FWONA SIRI FWONK BATRB LSXMK CRMLF CCO BATRA

Related Articles

BLDP: Ballard Power Systems Analysis and Research Report

2018-08-13 - Asif

Core Business At Ballard, Ballard Power Systems is building a clean energy growth company. Ballard Power Systems is recognized as a world leader in proton exchange membrane (“PEM”) fuel cell power system development and commercialization. The company's principal business is the design, development, manufacture, sale and service of PEM fuel cell products for a variety of applications, focusing on its power product markets of Heavy-Duty Motive (consisting of bus, truck, rail and marine applications), Portable Power, Material Handling and Backup Power, as well as the delivery of Technology Solutions, including engineering services, technology transfer, and the license and sale of its extensive intellectual property portfolio and fundamental knowledge for a variety of fuel cell applications. A fuel cell is an environmentally clean electrochemical device that combines hydrogen fuel with oxygen (from the air) to produce electricity. The hydrogen fuel can be obtained from natural g...

MARA: Marathon Patent Group Analysis and Research Report

2018-08-13 - Asif

Overview Marathon Patent Group was incorporated in the State of Nevada on February 23, 2010 under the name Verve Ventures, Inc. On December 7, 2011, the company changed its name to American Strategic Minerals Corporation and were engaged in exploration and potential development of uranium and vanadium minerals business. In June 2012, the company discontinued its minerals business and began to invest in real estate properties in Southern California. In October 2012, the company discontinued its real estate business when its former CEO joined the firm and the company commenced its IP licensing operations, at which time the Company’s name was changed to Marathon Patent Group, Inc. On November 1, 2017, the company entered into a merger agreement with Global Bit Ventures, Inc. (“GBV”), which is focused on mining digital assets. Marathon Patent Group has since purchased its cryptocurrency mining machines and established a data center in Canada to mine digital assets. Following the me...

ECYT: Endocyte Analysis and Research Report

2018-08-13 - Asif

Business and Organization Endocyte, Inc. is a biopharmaceutical company and leader in developing targeted therapies for the treatment of cancer. The Company uses drug conjugation technology to create novel therapeutics and companion imaging agents for personalized targeted therapies. The agents actively target receptors that are over-expressed on diseased cells relative to healthy cells, such as prostate specific membrane antigen (“PSMA”) in prostate cancer. This targeted approach is designed to safely enable the delivery of highly potent drug payloads. The companion imaging agents are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment. In September 2017, the Company entered into a Development and License Agreement (the “License Agreement”) with ABX advanced biochemical compounds – Biomedizinische Forschungsreagenzien GmbH (“ABX”), pursuant to which the Company acquired exclusive ...